Table 1.
Structure (Refer to Figure 3B for Structural Explanations) |
Affinity [Ki (nM)] 1 |
|||||
---|---|---|---|---|---|---|
Compound | X | Y | dNC 2 | MOR 3 | I2-IBS 4 | Ref. |
fentanyl (1.1) | - | - | - | 6 ± 1.5 5 | 5462 ± 1343 6 | [26] |
2.9 ± 1.5 | 8593 ± 738 | [28] | ||||
idazoxan (2.1) | - | - | - | - | 307 ± 183 6 | [26] |
28 ± 11 | [27,28] | |||||
BU224 (2.5) | - | - | - | - | 9.8 ± 0.3 | [48] |
2.6 | mPh | gu | 5 | 7.8 ± 2.5 5 | 1890 ± 499 6 | [26] |
2.7 | mPh | amim | 5 | 7119 ± 4089 5 | 9630 ± 6731 6 | [26] |
2.8 | -(CH2)3- | gu | 5 | 37 ± 12 5 | 2022 ± 949 6 | [26] |
23 ± 4.5 | 1920 ± 996 | [27] | ||||
2.9 | -(CH2)3- | amim | 5 | 1751 ± 1135 5 | 2327 ± 811 6 | [26] |
2.10 | -(CH2)2- | gu | 4 | 433 ± 83 | 437 ± 228 | [27] |
2.11 | -(CH2)4- | gu | 6 | 0.59 ± 0.18 | >10,000 | [28] |
2.12 | -(CH2)6- | gu | 8 | 1.04 ± 0.28 | 409 ± 238 | [27] |
2.13 | -(CH2)7- | gu | 9 | 0.37 ± 0.19 | 6627 ± 3106 | [28] |
2.14 | -(CH2)8- | gu | 10 | 37 ± 9.7 | 126 ± 72 | [27] |
2.15 | -(CH2)9- | gu | 11 | 26 ± 6 | 58 ± 46 | [28] |
2.16 | -(CH2)12- | gu | 14 | 477 ± 75 | 6.5 ± 3.0 | [27] |
2.17 | mXyl | gu | 7 | 0.0098 ± 0.0033 | >10,000 | [28] |
0.448 ± 0.079 7 | [49] | |||||
2.18 | -(CH2)3- | bu | 12 | 6142 ± 2123 | 875 ± 713 | [28] |
2.19 | -(CH2)6- | bu | 15 | 2168 ± 66 | 323 ± 270 | [28] |
2.20 | -(CH2)8- | bu | 17 | 339 ± 35 | >10,000 | [28] |
2.21 | -(CH2)12- | bu | 21 | 545 ± 179 | 547 ± 316 | [28] |
1 Ki, inhibition constant (nM) with standard error of the mean, 2 dNC—topological distance (number of bonds) between the nitrogen attached at the position 4 of the piperidine ring and the central carbon atom in guanidine, 2-aminoimidazoline or imidazoline moieties, see Figure S1C, 3 unless specified otherwise, competitive assays done in membrane preparations of post-mortem human frontal cortex, 2 nM [3H]DAMGO as radioligand, 4 unless specified otherwise, competitive assays done in membrane preparations of post-mortem human frontal cortex, 1 nM [3H]2-BFI as radioligand, 5 competitive assays done in neural membrane preparations of mice brain, 2 nM [3H]DAMGO as radioligand, 6 competitive assays done in neural membrane preparations of mice brain, 1 nM [3H]2-BFI as radioligand, 7 competitive assays done in membrane preparations of rat brain, 0.72 nM [3H]DAMGO as radioligand.